|By PR Newswire||
|March 19, 2014 11:00 PM EDT||
HATFIELD, England, March 20, 2014 /PRNewswire/ --
Joint research project awarded a Global Health Innovative Technology Fund grant
Eisai announced today that it has entered a collaboration with the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool (UoL) to identify new drugs that are effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of the parasitic tropical disease filariasis.
Under the collaboration, Eisai will work with the nonprofit LSTM to develop and implement new tools and technologies for the control and treatment of tropical diseases, and with UoL, a world-class institute that has made major contributions toward understanding the mechanisms of drug action of several classes of anti-parasitic drugs, to identify and develop novel drug candidates that efficiently eliminate the bacteria Wolbachia. Wolbachia live inside the parasitic worms, known as filariae, which cause lymphatic filariasis and onchocerciasis. These two filarial infectious diseases affect more than 150 million people worldwide. As filariae are dependent on Wolbachia bacteria for growth, development, reproduction and survival, the worms can be effectively eradicated by first eliminating the Wolbachia inside them.
While current anti-filarial treatments are effective against larvae and microfilariae, they require many years of consistent, annual mass drug administration in endemic communities to successfully eliminate the adult worms. Anti-Wolbachia therapy is expected to lead to worm sterility and effective worm eradication, thereby reducing treatment times and improving therapeutic outcomes compared to existing anti-filarial drugs. Furthermore, as anti-Wolbachia programmes are still in their infancy, this collaboration has the potential to provide a unique opportunity to make a significant contribution to communities affected by filariasis.
To date, the screening of more than 10,000 potential anti-Wolbachia compounds has revealed approximately 50 potentially promising compounds, leading to identification of about six chemotypes with anti-infective potential. Eisai and its collaboration partners will focus on two of these with the aim of identifying a single candidate for potential drug development within one to two years.
This unique approach has been awarded a two-year grant by the Global Health Innovative Technology Fund (GHIT Fund), an international non-profit organisation that aims to promote the discovery of new health technologies for eliminating infectious diseases prevalent in developing countries.
In support of the World Health Organisation (WHO)'s programme to eliminate lymphatic filariasis by 2020, Eisai is supplying diethylcarbamazine (DEC) free of charge to the WHO. Under its collaboration with LSTM and UoL, Eisai aims to make new treatments available as early as possible to help patients with filariasis and thereby increase further the healthcare benefits provided to these patients and their families in developing and emerging countries.
Notes to editors
About Anti-Wolbachia Therapy
Anti-Wolbachia therapy is a new method of treatment that eradicates the adult worms that can cause filariasis by eliminating bacteria known as Wolbachia that live in the cells of their bodies. This approach has the potential to significantly reduce the timescale of elimination programs, to provide alternatives to existing treatments, and to deliver tools that can be used in areas where current approaches are failing or cannot be deployed. Doxycycline, an antibiotic, is believed to work in this way and proof of concept has already been established in human field trials, which showed excellent results although requiring four to six weeks of daily treatment and being unsuitable for administration to children and pregnant women.
Under its collaboration with the Liverpool School of Tropical Medicine (LSTM) and University of Liverpool (UoL), Eisai will aim to identify potential new drug compounds that act more quickly and more effectively than doxycycline and that could be used across all population groups, and to develop these molecules to the stage of pre-clinical safety testing.
About Liverpool School of Tropical Medicine and the University of Liverpool
The LSTM is a non-profit charitable institution with a mission to develop and implement new tools and technologies for the control and treatment of tropical diseases. LSTM has an existing anti-Wolbachia program funded by the Bill and Melinda Gates Foundation and has developed assays and models to test compounds for anti-Wolbachia activity on a large scale.
The Department of Chemistry at the UoL has made major contributions toward understanding the mechanisms of drug action of several classes of anti-parasitic drugs. Over their 20 years in partnership, UoL and LSTM have adopted a "molecule to man" strategy to instigating its research projects, operating at all stages of the drug discovery pipeline up to and including clinical trials in humans. To date, a total of three projects have contributed to the portfolio of the Medicines for Malaria Venture (MMV), an organization that has developed the largest portfolio of anti-malarial drugs in history.
About the Global Health Innovative Technology Fund
The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization aimed at advancing the research and development of new health technologies from Japan to fight infectious diseases prevalent specifically in the developing world, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases (NTDs). Established as a public-private partnership between the Government of Japan, a consortium of pharmaceutical companies, and the Bill & Melinda Gates Foundation, the GHIT Fund facilitates and funds research and development of new health technologies through partnership creation and grant-making activities. For further information, please visit: http://www.ghitfund.org.
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
- Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc.
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Russia and the Middle East.
For further information please visit our web site http://www.eisai.co.uk
1. Filaria-EU 2014 http://www.filaria.eu/fil/fil.html
Date of preparation: March 2014
Job code: corporate-UK2026
"MathFreeOn.com is a line coding platform for engineers and scientists. When they want to solve an engineering problem and they have to use software - they have to pay a lot of money for licenses - but with MathFreeOn you don't have to pay a lot of money. Just go to our site and write the code and you can check the result right away," explained Simon Lee, CMO of MathFreeOn, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Cla...
Dec. 11, 2016 08:45 AM EST Reads: 560
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Dec. 11, 2016 08:00 AM EST Reads: 796
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal...
Dec. 11, 2016 07:30 AM EST Reads: 776
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, discussed how VPaaS enables you to move fast, creating scalable video experiences that reach your aud...
Dec. 11, 2016 07:00 AM EST Reads: 494
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
Dec. 11, 2016 06:45 AM EST Reads: 2,323
President Obama recently announced the launch of a new national awareness campaign to "encourage more Americans to move beyond passwords – adding an extra layer of security like a fingerprint or codes sent to your cellphone." The shift from single passwords to multi-factor authentication couldn’t be timelier or more strategic. This session will focus on why passwords alone are no longer effective, and why the time to act is now. In his session at 19th Cloud Expo, Chris Webber, security strateg...
Dec. 11, 2016 05:45 AM EST Reads: 743
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Dec. 11, 2016 05:30 AM EST Reads: 748
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 11, 2016 05:00 AM EST Reads: 1,190
"We are a leader in the market space called network visibility solutions - it enables monitoring tools and Big Data analysis to access the data and be able to see the performance," explained Shay Morag, VP of Sales and Marketing at Niagara Networks, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 11, 2016 04:45 AM EST Reads: 682
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Dec. 11, 2016 04:30 AM EST Reads: 884
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Dec. 11, 2016 03:30 AM EST Reads: 1,176
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
Dec. 11, 2016 03:00 AM EST Reads: 815
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for s...
Dec. 11, 2016 02:45 AM EST Reads: 926
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Dec. 11, 2016 02:45 AM EST Reads: 1,808
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2017 New York. The 20th Cloud Expo and 7th @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Internet to enable us all to im...
Dec. 11, 2016 02:30 AM EST Reads: 1,076